Preferences help
enabled [disable] Abstract
Number of results
2016 | 3 | 3 | 172-177
Article title

Miejscowe zastosowanie niesteroidowych leków przeciwzapalnych w terapii obrzęku plamki w oczach po pars plana witrektomii z endotamponadą olejem silikonowym – opis przypadków

Title variants
The use of nonsteroidal anti-inflammatory drugs in the treatment of macular edema in eyes after pars plana vitrectomy with silicon oil endotamponade – a case series report
Languages of publication
The aim of the study: To evaluate the influence of ophthalmic suspension of nepafenac on the central retina edema. Material and method: Three patients treated with a topical nonsteroidal anti- inflammatory drug nepafenac 0.1% ophthalmic suspension for the reduction of postoperative macular edema associated with pars plana vitrectomy with silicon oil endotamponade. In all patients macular morphology was assessed using optical coherence tomography and best corrected visual acuity with Snellen charts. Results: Improvement of macular morphology and central retinal thickness reduction were observed in all patients. Best corrected visual acuity remained unchanged during the follow-up period. Conclusion: Based on our observations we suggest that the involvement of the vitreous body in the distribution of ophthalmic suspension of a topical nonsteroidal anti-inflammatory drug within the posterior segment of the eye does not seem to be significant.
Cel pracy: Ocena wpływu miejscowego podania nepafenaku w postaci kropli do oka na obrzęk centralnej siatkówki. Materiał i metody: Trzech chorych w wieku średnio 68 lat leczono miejscowo niesteroidowym preparatem przeciwzapalnym 0,1% nepafenaku z powodu obrzęku plamki w oczach po pars plana witrektomii z endotamponadą olejem silikonowym. Ocenie poddano morfologię plamki za pomocą optycznej koherentnej tomografii i funkcję oka na podstawie badania ostrości wzroku na tablicach Snellena. Wyniki: U wszystkich chorych w obrazie optycznej koherentnej tomografii stwierdzono poprawę morfologii plamki z redukcją centralnej grubości siatkówki, najlepiej skorygowana ostrość wzroku utrzymywała się na tym samym poziomie w okresie obserwacji. Wniosek: Nasze obserwacje sugerują ograniczony udział ciała szklistego w transporcie wewnątrzgałkowym do tylnego odcinka oka niesteroidowych leków przeciwzapalnych podawanych w postaci kropli ocznych.
Physical description
  • 1. Lane SS, Modi SS, Lehmann RP, et al. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg 2007; 33: 53-58.
  • 2. Hariprasad SM, Callanan D, Gainery S, et al. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J Ocul Pharmacol Ther 2007; 23: 585-590.
  • 3. Singh R, Alpern L, Jaffe GJ, et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol 2012; 6: 1259-1269.
  • 4. Wolf EJ, Braunstein A, Shih C, et al. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J Cataract Refract Surg 2007; 33: 1546-1549.
  • 5. Walters T, Raizman M, Ernest P, et al. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg 2007; 33: 1539-1545.
  • 6. Gamache A, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 2000; 24: 357-370.
  • 7. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 1992; 36: 259-284.
  • 8. Smyth EM, Fitzgerald GA. The eicosanoids: prostaglandins, thromboxanes, leukotrienes & related compounds. In: Katzung B. (ed). Basic and Clinical Pharmacology. McGraw Hill, New York 2007: 293-308.
  • 9. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 2003; 27: 281-291.
  • 10. Ke TL, Graff G, Spellman JM, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000; 24: 371-384.
  • 11. Kulkarni PS, Srinivasan BD. Cyclooxygenase and lipoxygenase pathways in anterior uvea and conjunctiva. Prog Clin Biol Res 1989; 312: 39-52.
  • 12. Radi ZA, Render JA. The pathophysiologic role of cyclooxygenases in the eye. J Ocul Pharmacol Ther 2008; 24: 141-151.
  • 13. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin 2006; 22: 397-404.
  • 14. Bucolo C, Marrazzo G, Platania CBM, et al. Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation. J Pharm Pharmacol 2014; 66: 954-960.
  • 15. Koevary SB. Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metab 2003; 4: 213-222.
  • 16. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears ML (ed). Pharmacology of the Eye: Handbook of Experimental Pharmacology. Springer-Verlag, Berlin 1986: 19-116.
  • 17. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthamol 2002; 47: 41-52.
  • 18. Hughes PM, Olejnik O, Chang-Lin JE, et al. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005; 57: 2010-2032.
  • 19. Chastain JE, Sanders ME, Curtis MA, et al. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. Exp Eye Res 2016; 145: 58-67.
  • 20. Nardi M, Lobo C, Bereczki A, et al. Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery Clin Ophthalmol 2007; 1: 527-533.
  • 21. Modi SS, Lehmann RP, Walters TR, et al. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study. J Cataract Refract Surg 2014; 40: 203-211.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.